cancers-logo

Journal Browser

Journal Browser

Clinical and Surgical Therapy for Colorectal Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (30 November 2025) | Viewed by 1130

Special Issue Editor


E-Mail Website
Guest Editor
Department of Gastroenterological Surgery, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland
Interests: general surgery; colorectal cancer

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue, titled "Clinical and Surgical Therapy for Colorectal Cancer", in the journal Cancers. Colorectal cancer remains a leading global health challenge, but recent advances in surgical techniques and perioperative care have significantly improved outcomes. Procedures such as anterior resection and total mesorectal excision, and minimally invasive approaches, including robotic and laparoscopic surgeries, are enhancing precision, reducing complications, and improving recovery times. Additionally, integrating multidisciplinary strategies with surgery, such as total neoadjuvant therapy, has proven critical in optimizing treatment outcomes. Emerging research into the gut microbiome offers complementary insights, particularly in predicting therapy response, reducing postoperative complications, and supporting long-term recovery. Together, these advancements underline the importance of innovation in both surgical and adjunctive approaches to improve survival and quality of life for patients with colorectal cancer.

This Special Issue aims to explore the latest advancements in colorectal cancer surgery, including novel techniques, enhanced recovery pathways, and integrated therapeutic approaches. It will also touch upon the role of microbiome research in supporting surgical outcomes and quality of life. By addressing both clinical and surgical innovations, this Special Issue aligns with the journal’s focus on translational and clinical cancer research.

In this Special Issue, original research articles and reviews are welcome. Research areas may include, but are not limited to, the following topics:

  • Advances in surgical techniques, including minimally invasive and robotic approaches.
  • Anterior resection and total mesorectal excision outcomes.
  • Innovations in perioperative care and enhanced recovery after surgery (ERAS).
  • Role of neoadjuvant therapy (in particular total neoadjuvant therapy).
  • Postoperative complications, management, and long-term outcomes.
  • The interplay between the gut microbiome and postoperative recovery.
  • Quality of life and survivorship in patients following surgery.

We look forward to receiving your contributions.

Dr. Laura Koskenvuo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colorectal cancer
  • rectal cancer
  • anterior resection
  • minimally invasive surgery
  • robotic surgery
  • surgical oncology
  • neoadjuvant therapy
  • adjuvant therapy
  • quality of life
  • gut microbiome

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1160 KB  
Article
Immunotherapy Plus Surgery Improves Survival in Microsatellite Instability-High Colon Cancer with Isolated Peritoneal Metastases
by Daniel Aryeh Metzger, Yasmeen Chahal, Olivia Watman, Ying Li, Alessio Pigazzi, Despina Siolas and Mehraneh D. Jafari
Cancers 2025, 17(21), 3496; https://doi.org/10.3390/cancers17213496 - 30 Oct 2025
Viewed by 854
Abstract
Background: Microsatellite instability-high (MSI-H) colon cancer with isolated peritoneal metastases (iPM) represents a molecularly and anatomically distinct clinical subset with limited evidence to guide treatment. Given the unique immunogenic profile of MSI-H tumors and the historically poor prognosis of peritoneal dissemination, we evaluated [...] Read more.
Background: Microsatellite instability-high (MSI-H) colon cancer with isolated peritoneal metastases (iPM) represents a molecularly and anatomically distinct clinical subset with limited evidence to guide treatment. Given the unique immunogenic profile of MSI-H tumors and the historically poor prognosis of peritoneal dissemination, we evaluated the association of immunotherapy, chemotherapy, and surgery with survival outcomes in this population. Methods: Using the National Cancer Database, we identified patients with MSI-H colon cancer and iPM diagnosed between 2016–2021. Patients were stratified by systemic therapy type (immunotherapy, chemotherapy, combination) and surgical resection status. Kaplan–Meier and multivariable Cox regression analyses were used to assess overall survival (OS). Results: Among 598 patients, 22% received systemic treatment with immunotherapy and 76% underwent surgical resection. Immunotherapy was associated with significantly longer median OS compared to chemotherapy (33 vs. 18 months, p < 0.001). On multivariable analysis, immunotherapy remained independently associated with improved survival (HR: 0.46; p < 0.001). Surgical resection of the primary tumor with (HR: 0.40; p < 0.001) or without metastatectomy (HR: 0.41; p < 0.001) was associated with longer survival, and the combination of surgery and immunotherapy yielded the greatest survival benefit. Conclusions: Patients with MSI-H colon cancer and iPM treated with immunotherapy had significantly improved survival, compared to chemotherapy. Surgical resection combined with immunotherapy is associated with the greatest survival benefit, supporting a multimodal approach. These findings provide real-world evidence supporting integration of immunotherapy and surgery in this molecularly and anatomically distinct population. Full article
(This article belongs to the Special Issue Clinical and Surgical Therapy for Colorectal Cancer)
Show Figures

Figure 1

Back to TopTop